Reported rapid, significant and durable improvements in vision at twelve months
Concordant improvement in key secondary outcome measures
The target registration dose of sepofarsen was well-tolerated with a favorable benefit/risk profile
Strengthens confidence
… perception de la lumière (MVAC> 3,0 LogMAR) au départ, la population étudiée dans le cadre d' Illuminate était plus … d'acuité visuelle de l'Early Treatment of Diabetic Retinopathy Study (ETDRS ou Étude sur le traitement précoce de la rétinopathie diabétique) et le Test de vision rudimentaire de …
LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr.
… NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a biopharmaceutical company dedicated to changing lives through … In addition, ProQR has granted the underwriters a 30-day option to purchase up to 1,363,636 additional ordinary shares … dominant retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing …
… NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a biopharmaceutical company dedicated to changing lives through … In addition, ProQR has granted the underwriters a 30-day option to purchase up to 862,500 additional ordinary shares … for the offering. Kempen & Co is acting as the Company’s European financial advisor in relation to this offering. A …
… NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through … offering, ProQR has granted the underwriters a 30-day option to purchase up to 745,471 additional ordinary shares … as cystic fibrosis, Leber’s congenital amaurosis 10 and dystrophic epidermolysis bullosa. Based on our unique …